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Interaction of Coagulation Defects and
Cardiovascular Risk Factors
Increased Risk of Myocardial Infarction Associated With Factor V
Leiden or Prothrombin 20210A
Carine J.M. Doggen, MSc; Volkert Manger Cats, MD; Rogier M. Bertina, PhD;
Frits R. Rosendaal, MD
Background—A genetic variation located in the 39-untranslated region of the prothrombin gene (prothrombin 20210 G3A)
was recently described as a risk factor for venous thrombosis. We examined how the presence of this mutation affected the
risk of myocardial infarction in a population-based case-control study. Furthermore, we studied the risk of myocardial
infarction associated with the simultaneous presence of a coagulation defect (ie, the 20210 AG genotype of prothrombin
or the factor V Leiden mutation) and major cardiovascular risk factors.
Methods and Results—Among 560 men with a first myocardial infarction before the age of 70 years, 1.8% were heterozygous
carriers of the 20210 variant of the prothrombin gene. The control group consisted of 646 men who were frequency
matched by age. In the latter group, the frequency of the 20210 AG genotype was 1.2%. The risk of myocardial infarction
in the presence of the AG genotype was increased by 50% (odds ratio, 1.5; 95% confidence interval [95% CI], 0.6 to 3.8).
The risk of myocardial infarction for carriership of factor V Leiden mutation was increased by 40% (odds ratio, 1.4; 95%
CI, 0.8 to 2.2). When a coagulation defect was present (ie, the 20210 AG prothrombin genotype or the factor V Leiden
mutation), the risk of myocardial infarction for carriers versus noncarriers was 1.4 (95% CI, 0.9 to 2.2). This risk was
substantially increased when one of the major cardiovascular risk factors of smoking, hypertension, diabetes mellitus, or
obesity also was present, with odds ratios varying between 3 and 6. These risks exceeded those of the single effects of the
cardiovascular risk factors (ie, in the absence of the coagulation defect).
Conclusions—We conclude that in men the 20210 G3A variant of prothrombin is associated with an increased risk of
myocardial infarction. The combined presence of major cardiovascular risk factors and carriership of a coagulation defect
increases the risk considerably. (Circulation. 1998;97:1037-1041.)
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Recently, a genetic variation in the 39-untranslated region ofthe prothrombin (clotting factor II) gene was described
that was associated with an elevated prothrombin level.1
Individuals with a G3A transition at nucleotide 20210 (AG
genotype) had a mean prothrombin level of 1.32 U/mL,
whereas individuals with the GG genotype had a significantly
lower mean prothrombin level of 1.05 U/mL. Individuals with
the AG genotype had a 2.8-fold increased risk of venous
thrombosis compared with individuals with the 20210 GG
genotype in the Leiden Thrombophilia Study (LETS). In this
population-based case-control study, 6.2% of 474 unselected
consecutive patients with a first, objectively confirmed episode
of deep-vein thrombosis carried the prothrombin 20210A
allele compared with 2.3% of 474 control subjects matched for
age and sex. In a population of selected patients with a personal
and family history of venous thrombosis, 18% were carriers of
this allele.1
In only one study has the relation been studied of the
prothrombin variant (20210 G3A) and myocardial infarction.
In this case-control study in women 18 to 44 years old, the
presence of the AG genotype increased the risk of myocardial
infarction by 4.1-fold.2 In the same study, the 1691 G3A
mutation in the gene of clotting factor V (factor V Leiden),
which causes resistance to activated protein C, was shown to
be related to the occurrence of arterial thrombosis at a young
age: the risk of myocardial infarction was 2.3-fold increased in
heterozygotes for the factor V Leiden mutation.3 The AG
genotype of prothrombin gene and factor V Leiden mutation
both increased the risk of myocardial infarction, particularly in
the presence of other cardiovascular risk factors, such as
smoking or metabolic risk factors (obesity, diabetes, hyperten-
sion, hypercholesterolemia).2
In men, the association of the prothrombin 20210 G3A
genetic variant and myocardial infarction is unknown; we
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therefore studied the association of the genetic variation in the
39-untranslated region of the prothrombin gene and the factor
V Leiden mutation with myocardial infarction in the popula-
tion-based case-control Study of Myocardial Infarctions Lei-
den, which includes 560 men with a first myocardial infarction
and 646 control subjects. Second, we examined the interaction
between these genetic variations and other known cardiovas-
cular risk factors with regard to the risk of myocardial
infarction.
Methods
Subjects
We conducted the population-based case-control Study of Myocardial
Infarctions Leiden between July 1994 and February 1997.
Cases consisted of men with a first myocardial infarction before the
age of 70 years who were hospitalized in a university or general
hospital in Leiden, the Netherlands, between January 1990 and
January 1996. Two of the three characteristics of typical chest pain, a
transient rise in cardiac enzymes to more than twice the upper limit,
and ECG changes typical for myocardial infarction had to be present
in the discharge report or hospital record of a patient with myocardial
infarction. The study protocol was approved by the ethics committees
of both hospitals.
Control subjects also were men, who were frequency matched to
the patients (cases) by 10-year age groups, had undergone an ortho-
pedic intervention between January 1990 and May 1996, and had
received prophylactic anticoagulants for a short period after the
intervention. The orthopedic intervention varied from a plaster cast
for a ruptured hamstring to hip replacement. The control subjects
were identified in the records of the Leiden Anticoagulant Clinic; they
did not have a history of myocardial infarction and had not received
anticoagulants for $6 months before participation in the study.
Both patients and control subjects were born in the Netherlands and
were living in the Leiden region. Excluded were men with renal
disease (n510), severe (neuro)psychiatric problems (n528), or a life
expectancy of ,1 year (n516). The response among the remaining
patients and control subjects was 84.3% (560) and 77% (646),
respectively.
All persons completed a questionnaire concerning the presence of
cardiovascular risk factors such as smoking habits and alcohol con-
sumption. For patients, all questions referred to the period before the
myocardial infarction. The quetelet index was derived by dividing
weight (kg) by squared height (m2). Persons were considered obese if
their quetelet index exceeded 30 kg/m2. Medication use and history of
diabetes were determined through an interview with control subjects
and retrieved from discharge letters for the patients. A person was
classified as hypertensive or hypercholesterolemic when he was taking
prescription drugs for these conditions. The variables of obesity,
diabetes, hypertension, and hypercholesterolemia were grouped to-
gether as “metabolic risk factors.”3
Blood Collection and Laboratory Analysis
A morning fasting blood sample was drawn from the antecubital vein
into two Sarstedt Monovette tubes containing 0.106 mmol/L triso-
dium citrate. We separated the blood sample into plasma and cells
through centrifugation. High-molecular-weight DNA was extracted
from the white blood cells according to a salting-out method.4 The
DNA was stored at 4°C until amplification. Analyzable DNA was
available for 560 patients and 646 control subjects.
The status of the prothrombin variant (20210 G3A) was deter-
mined by the presence of a HindIII restriction site in the polymerase
chain reaction fragment according to the method of Poort et al.1
Genetic analysis of the factor V Leiden mutation (1691 G3A) was
performed with polymerase chain reaction as described previously.5
Heterozygous or homozygous carriership of the prothrombin
20210A allele or heterozygous or homozygous carriership of factor V
Leiden mutation was defined as a “coagulation defect.”
Statistical Analysis
An odds ratio (OR) was calculated as a measure of relative risk. This
OR estimates the risk of a myocardial infarction in the presence of a
risk factor relative to the absence of the particular risk factor, the
reference category. A 95% confidence interval (CI) was calculated
according to the method of Woolf.6 When the CI did not include
unity, the OR was different from unity at a significance level of #5%.
Multiple logistic regression was performed to adjust for age, with CIs
for the adjusted ORs calculated with the use of the standard errors of
the coefficients estimated according to the maximum likelihood
methods. Mean values are presented with standard deviation (SD). All
computations were carried out with the SPSS for Windows Version
7.0 statistical package.
Results
The characteristics of all patients and control subjects and
separately for those below the age of 50 years are shown in
Table 1. The mean age of the patients was 56.2 years (SD, 9.0
years), and that of control subjects was 57.3 years (SD, 10.8
years). A higher percentage of patients smoked and a lower
percentage used alcohol compared with the control subjects
(62.3% and 33.3% smoked and 80.4% and 86.8% consumed
alcohol, respectively). The risk factors of obesity, diabetes,
hypertension, and hypercholesterolemia were more often
found in patients than in control subjects, with the most
striking contrast in younger persons.
Prothrombin 20210A and Factor V
Leiden Mutation
In 10 of 560 patients (1.8%), the heterozygous (20210 AG)
genotype of prothrombin variant was detected compared with
8 of 646 control subjects (1.2%). Homozygous (20210 AA)
carriers were not found. The relative risk of myocardial
infarction associated with prothrombin 20210A carriership was
1.5 (95% CI, 0.6 to 3.8) (Table 2). In the subgroup of 314 men
aged #50 years, no increased risk was found (OR, 0.9; 95%
CI, 0.1 to 6.7). Only 4 persons in this young group were
carriers of the prothrombin 20210A allele: 2 patients and 2
control subjects.
The relative risk of myocardial infarction in the presence of
factor V Leiden mutation was 1.4 (95% CI, 0.8 to 2.2) (Table
2). One patient was a homozygous carrier of factor V Leiden
mutation (age 63 at the time of infarction). For the 314 men
below the age of 50, the risk was 1.8 (95% CI, 0.8 to 3.9).
Coagulation Defect
Overall, 48 patients (8.6%) and 39 control subjects (6.0%) had
a coagulation defect (ie, was a carrier of either prothrombin
20210A or factor V Leiden mutation). One individual (age 64
years) who was member of the control group was heterozygous
for both mutations. The relative risk of myocardial infarction
in the presence of a coagulation defect was 1.4 (95% CI, 0.9 to
2.2) overall and 1.6 (95% CI, 0.8 to 3.4) for men below the age
of 50.
Coagulation Defect and Interaction
Among smokers with the coagulation defect, the risk of a
myocardial infarction was increased sixfold compared with
nonsmokers without the abnormality. In comparison, smokers
without the abnormality had a relative risk of '3 (Table 3). A
similar indication of a synergistic effect was found for other risk
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factors (Tables 3 and 4). The single effect of obesity, diabetes,
hypertension, or hypercholesterolemia (ie, the presence of one
or more metabolic risk factors) was small without the concom-
itant presence of coagulation defect, whereas a substantial
increase in the risk of myocardial infarction was found when
the abnormality was present in combination with one of these
risk factors, ranging from a threefold to sixfold increase relative
to those with neither risk factor nor coagulation defect. No
clear evidence for synergy was found for persons using alcohol.
The individuals who account for the excess risks in the
different strata are not the same in each stratum in that only 21
of 87 persons with a coagulation defect had two or more
cardiovascular risk factors simultaneously.
Discussion
The results of our population-based case-control Study of
Myocardial Infarctions Leiden show that the mutation in the
prothrombin gene (20210 G3A) increases the risk of myo-
cardial infarction by 50% (OR, 1.5; 95% CI, 0.6 to 3.8). In
patients, 1.8% were heterozygous for the prothrombin 20210A
allele compared with 1.2% of control subjects. The risk of
myocardial infarction was increased considerably when a
coagulation defect (ie, the prothrombin 20210A allele or factor
V Leiden mutation) was present simultaneously with a cardio-
vascular risk factor, such as smoking.
In a population-based case-control study among women
aged 18 to 44 years, the risk of myocardial infarction associated
with carriership of prothrombin 20210A allele was 4.1 (95%
CI, 1.1 to 15.2), with 5.1% of the patients and 1.3% of the
control subjects being carriers of the prothrombin 20210A
allele.2 This risk was more pronounced than among men aged
#50 years in the present study, in whom we found no
increased risk. It should be noted, however, that only 4 young
men carried the prothrombin 20210A allele and that the CIs
were wide. Factors such as hormonal status and the use of oral
contraception might interact in the association of the pro-
thrombin 20210 G3A genetic variant and myocardial infarc-
TABLE 1. Characteristics of Patients* and Control Subjects in the Study of
Myocardial Infarctions Leiden
Characteristic
Overall <50 y
Patients
(n5560)
Control
Subjects
(n5646)
Patients
(n5154)
Control
Subjects
(n5160)
Age, y (mean [SD]) 56.2 (9.0) 57.3 (10.8) 44.4 (4.2) 42.5 (6.9)
Smoker, % 62.3 33.3† 77.3 41.3†
Alcohol user, % 80.4 86.8† 89 87.5
Obesity, %‡ 17.2 16.4 22.7 13.1†
Diabetes, % 4.6 3.4 4.5 1.9
Hypertension, %§ 18.9 16.6 7.1 4.4
Hypercholesterolemia, %§ 2.1 1.7 1.9 0.6
Metabolic risk factor, %\ 36.6 30.5† 31.2 18.8†
Coagulation defect, %¶ 8.6 6 12.3 8.1
*Data refer to the period before myocardial infarction.
†x2 test, P,.05.
‡For two persons, length and weight were not available.
§A person was classified as hypertensive or hypercholesterolemic if he was taking prescription drugs for
these conditions.
\Presence of one of the four metabolic risk factors of obesity, diabetes, hypertension, and
hypercholesterolemia.
¶Carriership of the prothrombin 20210A allele or factor V Leiden mutation was defined as a coagulation
defect.
TABLE 2. Frequency of the 20210 GA Genotypes in the
Prothrombin Gene, 1691 GA Genotypes in the Factor V Gene,
and Risk of Myocardial Infarction in 560 Patients and 646
Control Subjects
Genotype
Patients,
n (%)
Control
Subjects,
n (%)
Odds Ratio
(95% CI)*
Prothrombin (FII)
20210 GG 550 (98.2) 638 (98.8) 1.0†
20210 AG 10 (1.8) 8 (1.2) 1.5 (0.6–3.8)
20210 AA z z z z z z z z z
Factor V (FV)
1691 GG 522 (93.2) 614 (95.0) 1.0†
1691 AG‡ 37 (6.6) 32 (5.0) 1.4 (0.8–2.2)§
1691 AA 1 (0.2) z z z z z z
Coagulation defect
FII 20210 GG and
FV 1691 GG
512 (91.4) 607 (94.0) 1.0†
FII 20210 AG or
FV 1691 AG/AA
48 (8.6) 38 (5.9) 1.4 (0.9–2.2)\
FII 20210 AG and
FV 1691 AG
z z z 1 (0.2) z z z
*95% confidence interval.
†Reference category.
‡Thus, AG is heterozygous for factor V Leiden, and AA is homozygous for factor
V Leiden.
§Odds ratio of AG and AA genotypes versus GG genotype.
\Odds ratio of factor 20210 AG and/or factor V Leiden mutation versus neither.
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tion in women and account for the varying results between the
sexes. In addition, the previous study included women living
in western Washington, whereas our study was conducted in
men born in the Netherlands.
The prothrombin 20210A allele was found to be a risk factor
(OR, 2.8; 95% CI, 1.4 to 5.6) for deep-vein thrombosis in the
LETS study1 and two other recent reports.7,8 This relative risk
for venous thrombosis was more pronounced than that in our
case-control study of myocardial infarction. A discrepancy in
relative risks for venous and arterial thrombosis has also been
demonstrated for genetic variations in other clotting factors.
Factor V Leiden mutation (1691 G3A), for example, is the
most common risk factor for venous thrombosis. Heterozy-
gous carriers of the mutation have a sevenfold increased risk of
venous thrombosis9; homozygous individuals have a risk that is
increased up to 80-fold.10 However, results of studies in which
the factor V Leiden mutation was examined as a potential risk
factor for myocardial infarction are inconsistent,3,11 most likely
because the excess risk is less pronounced or present only in
specific groups.
When we consider the risk of myocardial infarction in the
presence of a coagulation defect (ie, carriership of the pro-
thrombin 20210A allele or factor V Leiden mutation), synergy
is found. Smokers, the obese, and persons with diabetes or
hypertension (ie, persons with one or more metabolic risk
factor) have, in combination with a coagulation defect, a
higher risk of myocardial infarction compared with noncarriers
with the particular cardiovascular risk factor. In each instance,
TABLE 3. Risk Effect of Smoking and a Metabolic Risk Factor, Without and With a Coagulation Defect
Cardiovascular Risk Factor Presence of Coagulation Defect
Patients,
n (%)*
Control Subjects,
n (%)* Odds Ratio (95% CI)†
No smoking No coagulation defect 193 (91.5) 403 (93.5) 1
FVL/20210A‡ 18 (8.5) 28 (6.5) 1.3 (0.7–2.5)
Smoking No coagulation defect 319 (91.4) 204 (94.9) 3.3 (2.5–4.2)
FVL/20210A 30 (8.6) 11 (5.1) 6.1 (3.0–12.5)
Non-metabolic No coagulation defect 332 (93.5) 420 (93.5) 1
FVL/20210A 23 (6.5) 29 (6.5) 1.0 (0.6–1.8)
Metabolic risk factor No coagulation defect 180 (87.8) 187 (94.9) 1.3 (1.0–1.6)
FVL/20210A 25 (12.2) 10 (5.1) 3.2 (1.5–6.7)
*Percentages are calculated within each stratum of cardiovascular risk factor (ie, among the nonsmoker control subjects, 6.5% were carriers of the factor V Leiden or
prothrombin 20210A).
†Odds ratios adjusted for age, with 95% confidence interval. Reference categories are noncarriers without the particular cardiovascular risk factor.
‡Factor V Leiden or prothrombin 20210A.
TABLE 4. Risk Effect of Obesity, Diabetes Mellitus, Hypertension, and Hypercholesterolemia, Without and With a
Coagulation Defect
Cardiovascular Risk Factor Presence of Coagulation Defect
Patients,
n (%)*
Control Subjects,
n (%)* Odds Ratio (95% CI)†
Nonobese No coagulation defect 427 (92.2) 505 (93.7) 1
FVL/20210A‡ 36 (7.8) 34 (6.3) 1.3 (0.8–2.0)
Obese No coagulation defect 84 (87.5) 101 (95.3) 1.0 (0.7–1.3)
FVL/20210A 12 (12.5) 5 (4.7) 2.8 (1.0–8.1)
Nondiabetic No coagulation defect 491 (92.0) 586 (93.9) 1
FVL/20210A 43 (8.0) 38 (6.1) 1.3 (0.9–2.1)
Diabetic No coagulation defect 21 (80.8) 21 (95.5) 1.2 (0.7–2.3)
FVL/20210A 5 (19.2) 1 (4.5) 5.9 (0.7–50.0)
Nonhypertensive No coagulation defect 419 (92.3) 505 (93.7) 1
FVL/20210A 35 (7.7) 34 (6.3) 1.2 (0.8–2.0)
Hypertensive No coagulation defect 93 (87.7) 102 (95.3) 1.2 (0.9–1.6)
FVL/20210A 13 (12.3) 5 (4.7) 3.3 (1.2–9.4)
Nonhypercholesterolemic No coagulation defect 502 (91.6) 597 (94.0) 1
FVL/20210A 46 (8.4) 38 (6.0) 1.4 (0.9–2.2)
Hypercholesterolemic No coagulation defect 10 (83.3) 10 (90.9) 1.2 (0.5–2.9)
FVL/2021OA 2 (16.7) 1 (9.1) 2.4 (0.2–26.7)
*Percentages are calculated within each stratum of cardiovascular risk factor (ie, among the nonobese control subjects, 6.3% were carriers of the factor V Leiden or
prothrombin 20210A).
†Odds ratios adjusted for age, with 95% confidence interval. Reference categories are noncarriers without the particular cardiovascular risk factor.
‡Factor V Leiden or prothrombin 20210A.
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the risk of the combination of the coagulation defect with a
risk factor exceeded the risk of the single risk factor. This is in
accordance with the results of the previous study in young
women, although the synergy was far more striking in that
study.2 It should be noted that the overall risk of myocardial
infarction is much lower in young women than in middle-aged
and elderly men (based on Dutch estimates (SIG Health Care
Information, National Medical Registration, tables on hospital
admissions, 1992 to 1994; available from Maliebaan 50, PO
Box 14066, 3508 SC Utrecht, Netherlands), with an incidence
of 1.5/10 000 person-years for women aged 35 to 39 years and
60/10 000 person-years for men aged 55 to 59 years). This
implies that in terms of public health or individual risk
estimates, an 1.5-fold increased risk in elderly men may be
more important than a fourfold increase in the risk among
young women. For every group of 10 000 men aged 55 to 59
years, there is an increase in the number of individuals
experiencing a myocardial infarction of 30, whereas among
every 10 000 women aged 35 to 39 years, the additional
number of patients with a myocardial infarction patients is 5.
The high background risk in elderly men also explains why
even with the large study population and powerful case-
control design of the present study, effects are more difficult to
detect than among young women and often do not reach
statistical significance.
The frequency of the prothrombin 20210 AG genotype in
control subjects in the Study of Myocardial Infarctions Leiden
was 1.2%, which is similar to that of the control group of the
case-control study among young women2 and equal to the
prevalence in 164 healthy plasma donors from the United
Kingdom.7 In the LETS study, however, the percentage
among healthy persons was 2.3%.1 We studied additional
control groups in the Netherlands to investigate this apparent
discrepancy: in patients with rheumatic arthritis, 5 of 291
(1.7%) were carriers of the prothrombin 20210A allele,
whereas in 249 blood donors, 8 carriers (3.2%) were found
(data not shown). These figures are in line with the actual
frequency of the prothrombin variant of 2%.12
The present study has two limitations. First, the results are
derived from men born in the Netherlands and do not
necessarily apply to other populations. The second is that of
necessity we studied patients who survived the myocardial
infarction. It cannot be excluded that patients who died during
the acute phase of the myocardial infarction more often carried
the prothrombin 20210A allele or factor V Leiden mutation.
We think this is unlikely, however, because survival of an
individual after myocardial infarction is influenced by other
factors, such as patient-induced delay and delay in receipt of
effective assistance, which affect the time period from the onset
of symptoms to the start of interventions such as thrombolytic
therapy.12 Several other factors influencing 30-day mortality
rates are the level of systolic blood pressure, heart rate, Killip
class, and localization of myocardial infarction.13 It does not
seem likely that the prothrombotic genotypes would play a
major role.
In conclusion, the results of the present study show that
genetic variations in thrombotic risk factors, such as prothrom-
bin 20210A and factor V Leiden mutation, increase the risk of
myocardial infarction in men. The risk is particularly increased
when other cardiovascular risk factors are present as well.
Given the high frequency of these genetic abnormalities in the
general population and the high prevalence of cardiovascular
risk factors, the need for prevention or treatment of these latter
risk factors is supported.
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